218. アルポート症候群 Alport syndrome Clinical trials / Disease details


臨床試験数 : 26 薬物数 : 33 - (DrugBank : 13) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 29

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05133050
(ClinicalTrials.gov)
January 1, 202227/10/2021Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 VariantsSafety and Efficacy of Early Angiotensin-converting Enzyme Inhibition in Patients With Alport Syndrome Carrying Pathogenic Heterozygous COL4A3,COL4A4 or COL4A5 MutationsAlport SyndromeDrug: RamiprilXinhua Hospital, Shanghai Jiao Tong University School of MedicineNULLNot yet recruiting30 Years50 YearsAll510N/AChina
2NCT01485978
(ClinicalTrials.gov)
March 20122/12/2011Efficacy and Safety Study to Delay Renal Failure in Children With Alport SyndromeEarly Prospective Therapy Trial to Delay Renal Failure in Children With Alport SyndromeRenal Insufficiency, ChronicDrug: Ramipril;Drug: placebo to ramiprilInstitut fuer anwendungsorientierte Forschung und klinische Studien GmbHUniversity Medical Center Goettingen;German Federal Ministry of Education and ResearchCompleted24 Months18 YearsAll66Phase 3Germany
3EUCTR2010-024300-10-DE
(EUCTR)
27/02/201212/12/2011Early prospective therapy trial to delay renal failure in children with Alport syndrome. - EARLY PRO-TECT AlportEarly prospective therapy trial to delay renal failure in children with Alport syndrome. - EARLY PRO-TECT Alport Alport's syndrome
MedDRA version: 19.1;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Delix
Product Name: Delix
Other descriptive name: RAMIPRIL
University Medical Center GöttingenNULLNot RecruitingFemale: yes
Male: yes
120Phase 3Germany